D4-PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of D4-PHARMA is 1.9% (moderate). The 2025 annual accounts show equity of €167,820 and a net result of €15,203. Equity is shrinking by ~3% per year across the filed fiscal years. Its solvency ranks better than 20% of 12,456 sector peers (NACE 47, fiscal year 2025). The company has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals.
Group and network
Connections & network
No directors read yet: 0 of 3 Gazette acts processed.